Urothelial Carcinoma Abstracts

217 abstracts

Abstract INTerpath-005: Phase II study of pembrolizumab (pembro) with V940 (mRNA-4157) versus pembro with placebo (pbo) for adjuvant treatment of resected high-risk muscle-invasive urothelial carcinoma (MIUC) Congress:ESMO 2024, Search all connections
Abstract Disparities in urothelial carcinoma (UC) drug approval: Contrasting North America and Europe Congress:ESMO 2024, Search all connections
Abstract Nephron-sparing surgery combined with perioperative systemic therapy in select high-risk upper tract urothelial carcinoma (UTUC) Patients: A pilot study for a prospective phase II trial Congress:ESMO 2024, Search all connections
Abstract Intrinsic molecular difference between bladder and upper tract urothelial carcinomas and its impacts in treatment response Congress:ESMO 2024, Search all connections
Abstract Overall survival (OS) results in phase II trial of cabozantinib (CABO) plus durvalumab (DURVA) in patients with urothelial carcinoma (UC) or non-UC variant histologies (VH) after platinum chemotherapy (ARCADIA) Congress:ESMO 2024, Search all connections
Abstract Assessing response durability and survival after second-line pembrolizumab in advanced urothelial carcinoma: A multicenter validation of a risk model Congress:ESMO 2024, Search all connections
Abstract Clinical outcomes of patients with metastatic urothelial carcinoma (mUC) discontinuing enfortumab vedotin (EV) monotherapy (mono) without disease progression Congress:ESMO 2024, Search all connections
Abstract Novel biomarker, ephrinB2 (B2), predicts resistance to treatment and poor overall survival (OS) metastatic urothelial carcinoma (mUC) Congress:ESMO 2024, Search all connections
Abstract Primary analysis of post-marketing surveillance (PMS) data for avelumab maintenance therapy in patients (pts) with curatively unresectable urothelial carcinoma (UC) in Japan Congress:ESMO 2024, Search all connections
Abstract Insights into second-line (2L) systemic treatment (tx) receipt in patients (pts) with metastatic urothelial carcinoma (mUC): Results of a retrospective observational study in Germany Congress:ESMO 2024, Search all connections
Abstract Updated efficacy profile of the double antibody drug conjugate (DAD) phase I trial: Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) in â‰¥ second line in metastatic urothelial carcinoma (mUC) Congress:ESMO 2024, Search all connections
Abstract Real-world (RW) characteristics and outcomes in patients (pts) with muscle-invasive urothelial carcinoma (MIUC) treated with adjuvant nivolumab (NIVO) with or without neoadjuvant chemotherapy (NAC) Congress:ESMO 2024, Search all connections
Abstract Subgroup analyses of patients (pts) with advanced urothelial carcinoma (aUC) who had long-term progression-free survival (PFS) or overall survival (OS) with avelumab first-line maintenance (1LM) in the AVENANCE real-world study Congress:ESMO 2024, Search all connections
Abstract MRG002-HER2 ADC combined with pucotenlimab (a PD-1 inhibitor), in patients with locally advanced or metastatic urothelial carcinoma (UC): Preliminary results of a phase I/II study Congress:ESMO 2024, Search all connections
Abstract Efficacy of enfortumab vedotin (EV) in patients (pts) with (w) advanced urothelial carcinoma (aUC) who have baseline neuropathy (N) and/or diabetes mellitus (DM): A UNITE study analysis Congress:ESMO 2024, Search all connections
Abstract Enfortumab vedotin (EV) + pembrolizumab (P) outcomes outside clinical trials and biomarkers of benefit in patients (pts) with advanced urothelial carcinoma: Analysis of the UNITE study Congress:ESMO 2024, Search all connections
Abstract Retrospective database analysis of real-world treatment patterns and sequencing in locally advanced or metastatic urothelial carcinoma patients receiving sacituzumab govitecan Congress:ESMO 2024, Search all connections
Abstract Feasibility and efficacy of split-dose cisplatin with atezolizumab for cisplatin-ineligible urothelial carcinoma (SOGUG-AUREA): Final results Congress:ESMO 2024, Search all connections
Abstract Cabozantinib plus durvalumab in patients with advanced and chemotherapy-treated urothelial carcinoma (UC) and variant histology (VH): An open-label, phase II, single-arm proof-of-concept trial: ARCADIA study. Subgroup analysis for bone metastasis Congress:ESMO 2024, Search all connections
Abstract Disitamab vedotin (DV) plus toripalimab (T) in unresectable locally advanced or metastatic urothelial carcinoma (la/mUC): Long-term outcomes from a phase Ib/II study Congress:ESMO 2024, Search all connections
Abstract Accurate detection of urothelial carcinoma by whole-genome methylation profiling of urinary cell-free DNA Congress:ESMO 2024, Search all connections
Abstract Efficacy of talazoparib and avelumab as a maintenance treatment in patients with advanced/metastatic urothelial carcinoma (mUC) whose disease did not progress after a first-line platinum-based chemotherapy (PBCT): The GETUG-TALASUR trial Congress:ESMO 2024, Search all connections
Abstract Avelumab first-line (1L) maintenance in advanced urothelial carcinoma (aUC): Conditional survival and long-term safety in patients (pts) treated for â‰¥1 or â‰¥2 years in JAVELIN Bladder 100 Congress:ESMO 2024, Search all connections
Abstract A phase II trial of intravesical cabazitaxel, gemcitabine, and cisplatin (CGC) for the treatment of non-muscle invasive BCG unresponsive urothelial carcinoma of the bladder Congress:ESMO 2024, Search all connections
Abstract Pre-treatment (Tx) risk factors for enfortumab vedotin-induced peripheral neuropathy (EVIPN) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of UNITE Congress:ESMO 2024, Search all connections
Abstract Phase I/II study of ipilimumab plus nivolumab combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma Congress:ESMO 2024, Search all connections
Abstract Study EV-103 dose escalation/cohort A (DE/A): 5y follow-up of first-line (1L) enfortumab vedotin (EV) + pembrolizumab (P) in cisplatin (CIS)-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC) Congress:ESMO 2024, Search all connections
Abstract BT8009 monotherapy in enfortumab vedotin (EV)-naÃ¯ve patients (pts) with metastatic urothelial carcinoma (mUC): Updated results of Duravelo-1 Congress:ESMO 2024, Search all connections
Abstract UriMee: A novel non-invasive test for diagnosis of urothelial carcinoma by detection of methylation markers in urinary sediment DNA Congress:ESMO 2024, Search all connections
Abstract Transformative diagnostics in urothelial carcinoma: Utilizing targeted NGS and LP-WGS for non-invasive detection and personalized medicine Congress:ESMO 2024, Search all connections
Abstract Different expression and prognostic implications of PD-L1 in tumor cells and immune cells with the SP263 monoclonal antibody in Chinese urothelial carcinoma patients. Congress:ASCO 2019, Search all connections
Abstract First-line PD(L)1 inhibitors for platinum-ineligible advanced urothelial carcinoma (aUC). Congress:ASCO 2019, Search all connections
Abstract Association of immune-related adverse events (irAEs) with clinical benefit in patients with metastatic urothelial carcinoma (mUC) treated with immune-checkpoint inhibitors (ICIs). Congress:ASCO 2019, Search all connections
Abstract Pretreatment eosinophil counts (PEC) in metastatic urothelial carcinoma (mUC) treated with anti-PD1/PD-L1 checkpoint inhibitors (CPI). Congress:ASCO 2019, Search all connections
Abstract Two sequential dose-dense regimens of CGP, followed by MVAC in patients with metastatic urothelial carcinoma (mUC): A single institution, explorative trial. Congress:ASCO 2019, Search all connections
Abstract Real-world outcomes of metastatic urothelial carcinoma (mUC) patients (pts) treated with first or second-line immunotherapies (IO) in the United States (US). Congress:ASCO 2019, Search all connections
Abstract Patient (pt) characteristics, treatment patterns, outcomes and prognostic factors in plasmacytoid urothelial carcinoma (PUC). Congress:ASCO 2019, Search all connections
Abstract Association of early bone metastases and outcomes of the bone predominant metastatic urothelial carcinoma (BP mUC) phenotype. Congress:ASCO 2019, Search all connections
Abstract Single cell analysis of urothelial carcinoma (UC) liver metastases identifies epithelial-mesenchymal transition (EMT) as a potential mechanism of resistance to immunotherapy. Congress:ASCO 2019, Search all connections
Abstract Sequencing chemotherapy and immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (UC): Meet-Uro1 study. Congress:ASCO 2019, Search all connections
Abstract Cost-effectiveness of pembrolizumab as second-line therapy for the treatment of locally advanced or metastatic urothelial carcinoma in the United States. Congress:ASCO 2019, Search all connections
Abstract Carboplatin-based chemotherapy (C) versus immunotherapy (IO) in metastatic urothelial carcinoma (mUC). Congress:ASCO 2019, Search all connections
Abstract CD205, a target antigen for a novel ADC: Evaluation of antigen expression on TNBC, pancreatic adenocarcinoma and bladder urothelial carcinoma. Congress:ASCO 2019, Search all connections
Abstract Concordance between PD-L1 assays for metastatic renal cell carcinoma (mRCC) and metastatic urothelial carcinoma (mUC). Congress:ASCO 2019, Search all connections
Abstract A cost-utility analysis of atezolizumab in the second-line treatment of metastatic urothelial carcinoma. Congress:ASCO 2019, Search all connections
Abstract Germline variants in urothelial carcinoma: Analysis of pathogenic and likely pathogenic variants in 645 subjects. Congress:ASCO 2019, Search all connections
Abstract A randomized phase II study of atezolizumab plus recombinant human IL-7 (CYT107) or atezolizumab alone in patients with locally advanced or metastatic urothelial carcinoma (mUC): A Cancer Immunotherapy Trials Network Trial (CITN-14). Congress:ASCO 2019, Search all connections
Abstract Retrospective analysis of the safety and efficacy of immune checkpoint inhibitors (CPI) among patients (pts) with pre-existing autoimmune disorders (AD) and renal cell carcinoma (RCC) or urothelial carcinoma (UC). Congress:ASCO 2019, Search all connections
Abstract 5-factor prognostic model for survival of patients with metastatic urothelial carcinoma receiving three different post-platinum PD-L1 inhibitors. Congress:ASCO 2019, Search all connections
Abstract Multi-omics profiling of upper-tract urothelial carcinomas. Congress:ASCO 2019, Search all connections
Abstract Recombinant humanized anti-PD-1 monoclonal antibody toripalimab in patients with metastatic urothelial carcinoma: Preliminary results of an open-label phase II clinical study. Congress:ASCO 2019, Search all connections
Abstract Interim analysis of the fierce-21 phase 2 (P2) study of vofatamab (B-701), a selective inhibitor of FGFR3, as salvage therapy in metastatic urothelial carcinoma (mUC). Congress:ASCO 2019, Search all connections
Abstract Immune correlates of CD73 expression in patients with urothelial carcinoma (UC). Congress:ASCO 2019, Search all connections
Abstract Analysis of EGFR mutant urothelial carcinoma (UC) reveals distinct mutational landscape. Congress:ASCO 2019, Search all connections
Abstract Adenocarcinoma (ACB), urothelial carcinoma (UCB) and squamous cell carcinoma (SCCB) of the bladder: A Comprehensive Genomic Profiling (CGP) Study. Congress:ASCO 2019, Search all connections
Abstract Erdafitinib in high-risk patients (pts) with advanced urothelial carcinoma (UC). Congress:ASCO 2019, Search all connections
Abstract FGFR-altered, advanced urothelial carcinoma (UC) and response to chemotherapy prior to receiving erdafitinib. Congress:ASCO 2019, Search all connections
Abstract Impact of immune-related adverse events on survival in patients with metastastic urothelial carcinoma treated with immune-checkpoint inhibitors. Congress:ASCO 2019, Search all connections
Abstract Gemcitabine plus carboplatin versus gemcitabine plus oxaliplatin in cisplatin unfit patients with advanced urothelial carcinoma: A randomized phase II study (COACH, KCSG GU10-16). Congress:ASCO 2019, Search all connections
Abstract Durability of complete response (CR) with atezolizumab (atezo) in locally advanced/metastatic urothelial carcinoma (mUC). Congress:ASCO 2019, Search all connections
Abstract Interim analysis of ibrutinib plus paclitaxel for patients with advanced urothelial carcinoma previously treated with platinum-based chemotherapy. Congress:ASCO 2019, Search all connections
Abstract Nivolumab monotherapy in patients with advanced platinum-resistant urothelial carcinoma: Efficacy and safety update from CheckMate 275. Congress:ASCO 2019, Search all connections
Abstract Clinical outcomes according to PD-L1 status and age in the prospective international SAUL study of atezolizumab (atezo) for locally advanced or metastatic urothelial carcinoma (UC) or non-UC of the urinary tract. Congress:ASCO 2019, Search all connections
Abstract Comprehensive genomic profiling (CGP) of upper-tract (UTUC) and bladder (BUC) urothelial carcinoma reveals opportunities for therapeutic and biomarker development. Congress:ASCO 2019, Search all connections
Abstract FIERCE-22: Clinical activity of vofatamab (V) a FGFR3 selective inhibitor in combination with pembrolizumab (P) in WT metastatic urothelial carcinoma, preliminary analysis. Congress:ASCO 2019, Search all connections
Abstract A phase II study of RC48-ADC in HER2-positive patients with locally advanced or metastatic urothelial carcinoma. Congress:ASCO 2019, Search all connections
Abstract Infigratinib in upper tract urothelial carcinoma vs urothelial carcinoma of the bladder and association with comprehensive genomic profiling/cell-free DNA results. Congress:ASCO 2019, Search all connections
Abstract CALGB 90601 (Alliance): Randomized, double-blind, placebo-controlled phase III trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma. Congress:ASCO 2019, Search all connections
Abstract Impact of clinicopathological features on survival in patients treated with immune-based combinations for metastatic urothelial carcinoma: A meta-analysis of randomized clinical trials. Congress:ASCO 2021, Search all connections
Abstract Outcomes of patients (pts) with advanced urothelial carcinoma (aUC) treated with immune checkpoint inhibitors (ICIs): Associations with age, race, sex and smoking history. Congress:ASCO 2021, Search all connections
Abstract Clinical safety and activity of cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced urothelial carcinoma (UC) after platinum chemotherapy (ARCADIA): Preliminary results from a nonrandomized, open-label, phase 2 trial. Congress:ASCO 2021, Search all connections
Abstract Efficacy of anti-PD(L)1 therapy for patients (Pts) with advanced urothelial carcinoma (aUC) with primary resistance to platinum-based chemotherapy (PC). Congress:ASCO 2021, Search all connections
Abstract Pathologic validation of artificial intelligence-powered prediction of combined positive score of PD-L1 immunohistochemistry in urothelial carcinoma. Congress:ASCO 2021, Search all connections
Abstract Opioid use in locally advanced or metastatic urothelial carcinoma patients and matched non-cancer controls. Congress:ASCO 2021, Search all connections
Abstract Patient outcomes following disease progression with enfortumab-vedotin (EV) in metastatic urothelial carcinoma (mUC). Congress:ASCO 2021, Search all connections
Abstract Is first-line immune checkpoint inhibitors (ICI) beneficial to platinum-eligible patients (pts) with advanced urothelial carcinoma (aUC)? a meta-analysis. Congress:ASCO 2021, Search all connections
Abstract A phase 3, multicenter, randomized study evaluating the efficacy of TAR-200 in combination with cetrelimab versus concurrent chemoradiotherapy in participants with muscle-invasive urothelial carcinoma of the bladder. Congress:ASCO 2021, Search all connections
Abstract RC48-ADC combined with toripalimab, an anti-PD-1 monoclonal antibody (Ab), in patients with locally advanced or metastatic urothelial carcinoma (UC): Preliminary results of a phase Ib/II study. Congress:ASCO 2021, Search all connections
Abstract Camrelizumab plus famitinib for advanced renal cell carcinoma or unresectable urothelial carcinoma: Updated results from a phase II trial. Congress:ASCO 2021, Search all connections
Abstract Real-world treatment patterns and clinical outcomes among patients with metastatic urothelial carcinoma. Congress:ASCO 2021, Search all connections
Abstract Quality of life, functioning, and symptoms in patients with previously treated locally advanced or metastatic urothelial carcinoma from EV-301: A randomized phase 3 trial of enfortumab vedotin versus chemotherapy. Congress:ASCO 2021, Search all connections
Abstract Impact of recurrence on health-related quality of life in patients at high risk of recurrence after radical surgery for muscle-invasive urothelial carcinoma (MIUC): Results from the phase 3 CheckMate 274 trial. Congress:ASCO 2021, Search all connections
Abstract Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who receive second-line immunotherapy. Congress:ASCO 2021, Search all connections
Abstract Phase I/II study to evaluate the efficacy of TAS0313, a cancer peptide vaccine, combined with pembrolizumab for locally advanced or metastatic urothelial carcinoma. Congress:ASCO 2021, Search all connections
Abstract Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC) in the JAVELIN Bladder 100 trial: Subgroup analysis by duration of treatment-free interval (TFI) from end of chemotherapy to start of maintenance. Congress:ASCO 2021, Search all connections
Abstract Study EV-103: Update on durability results and long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma (la/mUC). Congress:ASCO 2021, Search all connections
Abstract Avelumab first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): Analysis of time to end of next-line therapy in JAVELIN Bladder 100. Congress:ASCO 2021, Search all connections
Abstract Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Analysis of clinical and genomic subgroups from the JAVELIN Bladder 100 trial. Congress:ASCO 2021, Search all connections
Abstract A randomized phase II study comparing cisplatin and gemcitabine with or without berzosertib in patients with advanced urothelial carcinoma. Congress:ASCO 2021, Search all connections
Abstract Inducible T-cell co-stimulatory (ICOS) receptor agonist, feladilimab (fela), alone and in combination (combo) with pembrolizumab (P): Results from INDUCE-1 urothelial carcinoma (UC) expansion cohorts (ECs). Congress:ASCO 2021, Search all connections
Abstract Real-world, population-based study of treatments, survival and healthcare use in advanced urothelial carcinoma of the bladder. Congress:ASCO 2022, Search all connections
Abstract Molecular mechanism in urothelial carcinoma with FGFR3 mutation. Congress:ASCO 2022, Search all connections
Abstract Five-year survival stratification using “the Cancer Of the Bladder Risk Assessment” (COBRA) score for micropapillary and sarcomatoid urothelial carcinoma of the bladder variants. Congress:ASCO 2022, Search all connections
Abstract Insights into mutational differences between upper tract urothelial carcinoma and urothelial carcinoma of the bladder. Congress:ASCO 2022, Search all connections
Abstract EA8185: Phase 2 study of bladder-sparing chemoradiation (chemoRT) with durvalumab in clinical stage III, node-positive urothelial carcinoma (INSPIRE), an ECOG-ACRIN/NRG collaboration. Congress:ASCO 2022, Search all connections
Abstract 89Zirconium-labelled girentuximab (89Zr-TLX250) PET in patients with urothelial cancer (ZiPUP): A phase I trial of a novel staging modality for urothelial carcinoma. Congress:ASCO 2022, Search all connections
Abstract Trial in progress: A phase II switch maintenance study of live biotherapeutic MRx0518 and avelumab in patients with unresectable locally advanced or metastatic urothelial carcinoma (UC) who did not progress on first-line platinum-containing chemotherapy. Congress:ASCO 2022, Search all connections
Abstract A phase III randomized trial of eribulin (E) with or without gemcitabine versus standard of care (SOC) for metastatic urothelial carcinoma (UC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937. Congress:ASCO 2022, Search all connections
Abstract Prognostic factors and clinical outcomes in patients with upper tract urothelial carcinoma undergoing surgery: The Cleveland Clinic experience. Congress:ASCO 2022, Search all connections
Abstract Evaluating oncologists’ practice patterns and decision-making in locally advanced or metastatic urothelial carcinoma (la/mUC): The U.S. physician PARADIGM study (Part 2). Congress:ASCO 2022, Search all connections
Abstract A classification system for urothelial carcinoma (UC) defined by genomic drivers and the tumor microenvironment (TME) is predictive of immunotherapy response. Congress:ASCO 2022, Search all connections
Abstract Artificial intelligence algorithms for the diagnosis of urothelial carcinoma based on urine cytology: A noninvasive and efficient diagnostic approach. Congress:ASCO 2022, Search all connections
Abstract Novel use of ctDNA to identify muscle-invasive and non-organ-confined upper tract urothelial carcinoma. Congress:ASCO 2022, Search all connections
Abstract Clinical utility of urine DNA for noninvasive detection and minimal residual disease monitoring in urothelial carcinoma. Congress:ASCO 2022, Search all connections
Abstract Phase Ib study of avelumab and novel AXL inhibitor avb-S6-500 in patients with metastatic urothelial carcinoma (mUC). Congress:ASCO 2022, Search all connections
Abstract Benchmarking maintenance therapy survival in first-line advanced urothelial carcinoma using disease modeling. Congress:ASCO 2022, Search all connections
Abstract Toripalimab (anti-PD-1) monotherapy as a second-line treatment for patients with metastatic urothelial carcinoma (POLARIS-03): Two-year survival update and biomarker analysis. Congress:ASCO 2022, Search all connections
Abstract A prospective exploratory clinical study of penpulimab plus anlotinib as first-line treatment for locally advanced or metastatic urothelial carcinoma. Congress:ASCO 2022, Search all connections
Abstract Assessment of a HER-2 scoring system and its correlation of HER2-targeting antibody-drug conjugate therapy in urothelial carcinoma. Congress:ASCO 2022, Search all connections
Abstract Germline variants across self-reported racial populations with urothelial carcinoma (UC). Congress:ASCO 2022, Search all connections
Abstract Real-world treatment patterns and clinical outcomes with first-line therapy in cisplatin-eligible and ineligible patients with advanced urothelial carcinoma. Congress:ASCO 2022, Search all connections
Abstract Health-related quality of life (HRQoL) for patients with advanced/metastatic urothelial carcinoma (UC) enrolled in KEYNOTE-052 who are potentially platinum ineligible. Congress:ASCO 2022, Search all connections
Abstract Phase Ib study of anti-PD-L1 monoclonal antibody socazolimab in combination with nab-paclitaxel as first-line therapy for advanced urothelial carcinoma. Congress:ASCO 2022, Search all connections
Abstract Prognostic impact of bone metastasis in patients with metastatic urothelial carcinoma (mUC) treated with durvalumab (D) with or without tremelimumab (T) in the DANUBE study. Congress:ASCO 2022, Search all connections
Abstract Long-term outcomes in patients with advanced urothelial carcinoma (UC) who received avelumab first-line (1L) maintenance with or without second-line (2L) treatment: Exploratory analyses from JAVELIN Bladder 100. Congress:ASCO 2022, Search all connections
Abstract Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from JAVELIN Bladder 100 in subgroups defined by response to 1L chemotherapy. Congress:ASCO 2022, Search all connections
Abstract A phase I trial of elimusertib in combination with cisplatin or with cisplatin plus gemcitabine in advanced solid tumors with an emphasis on urothelial carcinoma. Congress:ASCO 2022, Search all connections
Abstract Phase 1a/b open-label study of IK-175, an oral AHR inhibitor, alone and in combination with nivolumab in patients with locally advanced or metastatic solid tumors and urothelial carcinoma. Congress:ASCO 2022, Search all connections
Abstract Preliminary results of a phase Ib/II combination study of RC48-ADC, a novel humanized anti-HER2 antibody-drug conjugate (ADC) with toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) in patients with locally advanced or metastatic urothelial carcinoma. Congress:ASCO 2022, Search all connections
Abstract A phase II study of RC48-ADC in HER2-negative patients with locally advanced or metastatic urothelial carcinoma. Congress:ASCO 2022, Search all connections
Abstract RC48-ADC for metastatic urothelial carcinoma with HER2-positive: Combined analysis of RC48-C005 and RC48-C009 trials. Congress:ASCO 2022, Search all connections
Abstract Perioperative chemoimmunotherapy with durvalumab for operable muscle-invasive urothelial carcinoma (MIUC): Primary analysis of the single arm phase II trial SAKK 06/17. Congress:ASCO 2022, Search all connections
Abstract Long-term outcomes in EV-301: 24-month findings from the phase 3 trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma. Congress:ASCO 2022, Search all connections
Abstract A randomised, double blind, phase II clinical trial of maintenance cabozantinib following chemotherapy for metastatic urothelial carcinoma (mUC): Final analysis of the ATLANTIS cabozantinib comparison. Congress:ASCO 2022, Search all connections
Abstract Cabozantinib (C) in combination with atezolizumab (A) in urothelial carcinoma (UC): Results from Cohorts 3, 4, 5 of the COSMIC-021 study. Congress:ASCO 2022, Search all connections
Abstract Clinician-patient insights and alignment on urothelial carcinoma care. Organization:PlatformQ Health Edu...,Needham, MA,BCAN, Search all connections
Abstract Clinical efficacy analysis of patients (pts) with HER-2 expressing metastatic urothelial carcinoma (mUC) treated with enfortumab vedotin (EV). Organization:MD Anderson Hematolo...,The University of Te...,Baylor College of Me..., Search all connections
Abstract Prognostic value of DNA damage repair and tolerance factors in patients with muscle-infiltrating urothelial carcinoma. Organization:2nd Department of On...,Cancer Research Inst...,Department of Pathol...,Drug:Cisplatin,Target:DNA,Congress:ASCO 2023, Search all connections
Abstract Tislelizumab (Tisle) combined with/without gemcitabine and cisplatin (GC) as adjuvant therapy in patients at high risk after upper urothelial carcinoma (UTUC) surgery: A real-world study. Organization:XIjing Hospital of A...,Xi’an, China,Xijing Hospital Four...,Drug:tislelizumab,GCSF,FF-10832, Search all connections
Abstract Characterizing immune-genomic signatures associated with response to immune checkpoint inhibitors (ICI) in patients with metastatic urothelial carcinoma (mUC). Organization:Cleveland Clinic Ler...,John D. Dingell VA H...,Cleveland Clinic Tau...,Drug:Atezolizumab,pembrolizumab,Target:PD-L1,PD-1, Search all connections
Abstract Real world genomics in metastatic urothelial carcinoma (mUC). Organization:University Hospitals...,Department of Intern...,Department of Medica..., Search all connections
Abstract Identification of prognostic biomarkers in plasma of patients with metastatic urothelial carcinoma (mUC). Organization:2nd Department of On...,Cancer Research Inst...,Biomedical Research ...,Drug:Cisplatin,Target:DNA, Search all connections
Abstract EV-203: Phase 2 trial of enfortumab vedotin in patients with previously treated advanced urothelial carcinoma in China. Clinical trial:7465-CL-1104,Organization:Astellas (China) Inv...,Seagen, Bothell, WA,Astellas Pharma, Inc...,Drug:Enfortumab vedotin,Target:MMAE,Nectin-4, Search all connections
Abstract Multiple antigen stimulating cellular therapy (MASCT)-I for metastatic urothelial carcinoma (mUC): A multicenter, phase I study (MASCT-I-1001). Clinical trial:HRYZ MASCT-I-1001,Organization:Sun Yat-sen Universi...,Department of Medica...,State Key Laboratory..., Search all connections
Abstract Blood eosinophils as prognostic biomarkers for advanced urothelial carcinoma in patients treated with avelumab: First results of the MALVA study (Meet-URO 25). Organization:Clinical Oncology Un...,Careggi University H...,Florence, Italy, Search all connections
Abstract Phase 2 study of HDAC inhibitor tucidinostat in combination with anti-PD-1 antibody in patients with locally advanced or metastatic urothelial carcinoma. Organization:Sun Yat-sen Universi...,Department of Urolog...,State Key Laboratory...,Drug:Tucidinostat,tislelizumab,Target:PD-1,histone deacetylase ..., Search all connections
Abstract Functional roles of tissue factor and EMMPRIN/CD147 present on bladder urothelial carcinoma-derived extracellular vesicles. Organization:Division of Experime...,Drug:tinzaparin,CD147 inhibitor,Target:Tissue Factor (TF),TFPI,CD147,Congress:ASCO 2023, Search all connections
Abstract Enhanced detection and characterization of targetable EGFR and ERBB2 exon20 insertion mutations in urothelial carcinoma. Organization:University of North ...,UNC Hosps,University of North ...,Drug:Mobocertinib,Erlotinib, Search all connections
Abstract Early safety and efficacy from a phase I clinical study of TWP-101, a novel CD137 agonist antibody, in patients with advanced melanoma and urothelial carcinoma. Organization:Peking University Ca...,Key Laboratory of Ca...,Ministry of Educatio...,Drug:TWP-101,Target:CD137,Congress:ASCO 2023, Search all connections
Abstract Phase 2 trial of intravesical cabazitaxel, gemcitabine, and cisplatin (CGC) for the treatment of non-muscle invasive BCG unresponsive urothelial carcinoma of the bladder. Organization:Columbia University ...,Columbia University ...,Columbia University ...,Drug:cabazitaxel,FF-10832,Cisplatin,Target:Gemcitabine,DNA, Search all connections
Abstract ALTER-UC-007: A prospective phase 2 study of anlotinib with gemcitabine and cisplatin or anlotinib with penpulimab as perioperative treatment for patients with muscle-invasive urothelial carcinoma (MIUC). Organization:Department of Urolog...,Fudan University Sha...,Shanghai, China, Gra...,Drug:Anlotinib,FF-10832,Cisplatin,Target:Gemcitabine, Search all connections
Abstract A phase III randomized trial of eribulin (E) with or without gemcitabine vs standard of care (SOC) for metastatic urothelial carcinoma (UC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937. Clinical trial:NCI-2020-07651,Organization:SWOG Statistics and ...,University of Califo...,Fred Hutchinson Canc..., Search all connections
Abstract A phase II study of olaparib (AZD2281) in patients (Pts) with metastatic/advanced urothelial carcinoma and other genitourinary (GU) tumors with DNA-repair defects. Clinical trial:NCI-2017-02296,Organization:National Cancer Inst...,NYU Langone Laura an...,Dana-Farber Cancer I..., Search all connections
Abstract Survival outcomes of sarcomatoid versus classic urothelial carcinoma of bladder. Organization:Miami Cancer Institu...,Baptist Health South...,Florida Internationa...,Drug:Cisplatin,immunotherapy,Target:TERT,C228T, Search all connections
Abstract Clinical utility of plasma ctDNA sequencing in metastatic urothelial carcinoma. Organization:Institut Gustave Rou...,Gustave Roussy and P...,Gustave Roussy Dépar...,Drug:immunotherapy,Target:FGFR3, Search all connections
Abstract EphrinB2 (B2) expression predicts poor response to PD1/L1 antibodies (Ab) in metastatic urothelial carcinoma (mUC). Organization:University of Southe...,Vasgene Therapeutics...,Rutgers University,Drug:sEphB4-HSA,pembrolizumab, Search all connections
Abstract Activity of cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced urothelial carcinoma (UC) or non-UC variant histologies (VH) after platinum chemotherapy: Interim results from the phase 2 ARCADIA trial. Organization:IRCCS Foundation Nat...,Department of Medica...,IRCCS Ospedale San R..., Search all connections
Abstract Biomarkers of response to sacituzumab govitecan (SG) and efficacy after treatment with enfortumab vedotin (EV) in advanced urothelial carcinoma (aUC): Analysis of the UNITE study. Organization:University of Califo...,Helen Diller Family ...,MD Anderson Hematolo..., Search all connections
Abstract Independent biomarkers predictive of outcomes with enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study. Organization:University of Califo...,Helen Diller Family ...,University of Califo..., Search all connections
Abstract Mismatch repair deficiency and microsatellite instability-high in urothelial carcinoma: A systematic review and meta-analysis. Organization:National Cancer Inst...,Memorial Sloan Kette...,National Institutes ...,Drug:immunotherapy,Target:Microsatellite Insta...,Mismatch Repair Defi...,Congress:ASCO 2023, Search all connections
Abstract Disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate (ADC), combined with toripalimab in patients with locally advanced or metastatic urothelial carcinoma: An open-label phase 1b/2 study. Organization:Peking University Ca...,Peking University Fi...,Affiliated Drum Towe..., Search all connections
Abstract Long-term safety of avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC) in the JAVELIN Bladder 100 trial. Clinical trial:B9991001,Organization:Dana-Farber Cancer I...,Harvard Medical Scho...,Inova Schar Cancer I..., Search all connections
Abstract Impact of histology on the efficacy and safety of pembrolizumab (pembro) monotherapy for advanced urothelial carcinoma (UC) in the phase 3 KEYNOTE-045 and KEYNOTE-361 trials. Organization:Fondazione IRCCS Ist...,Cliniques Universita...,Aichi Medical Univer..., Search all connections
Abstract Estimated net benefit of avelumab (AVE) + best supportive care (BSC) vs BSC alone for patients (pts) with advanced urothelial carcinoma (aUC) using a quality-adjusted time without cancer symptoms or toxicity (Q-TWiST) analysis. Clinical trial:B9991001,Organization:Barts Cancer Institu...,Experimental Cancer ...,Queen Mary Universit..., Search all connections
Abstract Outcomes by complete response to first-line pembrolizumab or platinum-based chemotherapy in advanced urothelial carcinoma (UC) in KEYNOTE-361. Clinical trial:3475-361,Organization:Adana Baskent Üniver...,Adelaide and Meath H...,University College D..., Search all connections
Abstract Fibroblast growth factor receptor 3 (FGFR3) alterations in PROOF 302: A phase III trial of infigratinib (BGJ398) as adjuvant therapy in patients (pts) with invasive urothelial carcinoma (UC). Clinical trial:QBGJ398-302,Organization:Fred Hutchinson Canc...,Seattle Cancer Care ...,USC Institute of Uro..., Search all connections
Abstract Utilization of neoadjuvant chemotherapy (NAC) and pathologic outcomes in upper tract urothelial carcinoma (UTUC). Organization:George Washington Un...,Drexel University Co...,Johns Hopkins Univer...,Congress:ASCO 2024, Search all connections
Abstract Development and validation of a novel prognostic model for overall survival in patients with micropapillary urothelial carcinoma. Organization:University of the Ae...,Democritus Universit...,Congress:ASCO 2024, Search all connections
Abstract Non-invasive detection of urothelial carcinoma through ensembled methylation profiles and fragmentomic patterns in urinary cell-free DNA. Organization:National Cancer Cent...,National Clinical Re...,Cancer Hospital, Chi...,Congress:ASCO 2024, Search all connections
Abstract Comparative outcomes of radical nephroureterectomy and kidney-sparing surgery in the treatment of high-grade upper tract urothelial carcinoma. Organization:Rutgers-RWJ Medical ...,Congress:ASCO 2024, Search all connections
Abstract Gemcitabine/paclitaxel/adriamycin (GTA) as a nephron-sparing regimen in urothelial carcinoma: The MD Anderson Cancer Center (MDACC) experience. Organization:UT Health Sciences C...,Congress:ASCO 2024, Search all connections
Abstract Tumor immune microenvironment analysis and MRI results of a phase II trial investigating tislelizumab (T) in the neoadjuvant treatment of high-risk upper tract urothelial carcinoma (UTUC). Drug:PD-1/L1 checkpoint i...,Trastuzumab,Target:PD-1,PD-L1,Organization:Ren Ji Hospital,Renji Hospital Shang...,Clinical trial:NEO-IO,Congress:ASCO 2024, Search all connections
Abstract Baseline geriatric 8 (G8) screening tool to predict overall survival in metastatic urothelial carcinoma treated with immune checkpoint inhibitors. Organization:Augusta University/U...,Department of Biosta...,Congress:ASCO 2024, Search all connections
Abstract Neoadjuvant cisplatin-based chemotherapy followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of the bladder: Post hoc analysis of two prospective studies. Organization:Soonchunhyang Univer...,Soonchunhyang Univer...,Dankook University H...,Congress:ASCO 2024, Search all connections
Abstract Disitamab vedotin (DV, RC48-ADC) combined with cadonilimab (anti-PD-1/CTLA-4 bispecific antibody) in patients with locally advanced or metastatic urothelial carcinoma (la/mUC): An open-label, single-arm, phase II study. Drug:RC48-ADC,Cadonilimab,Target:CTLA-4,PD-1,HER2 (ERBB2),Organization:Cancer Hospital Affi...,General Internal Med...,Clinical trial:AK104-RC48 UC 01, Search all connections
Abstract Prognostic analysis of disitamab vedotin combined with PD-1 inhibitor first-line treatment in advanced urothelial carcinoma: A propensity score analysis. Drug:Disitamab vedotin,PD-1 inhibitor TIS,tislelizumab,Target:Gemcitabine, Search all connections
Abstract Livmoniplimab with or without budigalimab in patients with advanced solid tumors: Results from the combination therapy in the urothelial carcinoma dose expansion cohort. Drug:Livmoniplimab,budigalimab,Target:GARP:TGF-β1 complex,PD-1,Organization:Hospital Clínico Uni...,Universite Catholiqu...,Division of Hematolo..., Search all connections
Abstract Maintenance therapy with avelumab as the first-line treatment in patients with metastatic urothelial carcinoma: A real-world, ambispective RAVE-Bladder study. Drug:avelumab,Gemcitabine,Cisplatin,Target:Avelumab,Gemcitabine,PD-L1, Search all connections
Abstract Comparison of clinical outcomes of bladder preservation and surgery in a real-world study of patients with muscle invasive urothelial carcinoma using urine and plasma based MRD (minimal residual disease) assays. Organization:Rush University Medi...,Vanderbilt-Ingram Ca...,Congress:ASCO 2024, Search all connections
Abstract Subgroup analysis of real-world efficacy of enfortumab vedotin in patients with metastatic/locally advanced urothelial carcinoma from a European database. Organization:Charité University M...,Rotkreuzklinikum Mun...,Heinrich-Heine-Unive..., Search all connections
Abstract Costs associated with novel first-line (1L) treatments in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC) from a United States (US) Medicare and commercial payer perspective. Drug:Enfortumab vedotin,pembrolizumab,nivolumab,Target:PD-1,Nectin-4,PD-L1, Search all connections
Abstract Characterizing genomic alterations in patients with metastatic urothelial carcinoma (mUC) treated with enfortumab-vedotin (EV) with a focus on 1q23.3. Organization:CFCE - Dana-Farber C...,Mass General Brigham,Congress:ASCO 2024, Search all connections
Abstract Real-world evidence for enfortumab vedotin (EV) in metastatic urothelial carcinoma (mUC): a multi-centred observational study in a publicly funded Canadian system. Organization:Department of Medica...,Congress:ASCO 2024, Search all connections
Abstract Integrative genomic analysis examines molecular and clinical disparities between bladder urothelial carcinoma and upper tract urothelial carcinoma. Drug:platinum-based chemo...,immunotherapy,Target:TP53,FGFR3,CREBBP,Organization:Konyang University H...,Congress:ASCO 2024, Search all connections
Abstract SOGUG-AVELUMAB_RWD: Comprehensive analysis of real-word data to evaluate the effectiveness and safety of avelumab maintenance therapy in patients with stage IV urothelial carcinoma conducted in Spain. Organization:Hospital Universitar...,Servicio Murciano de...,Hospital de Sagunto, Search all connections
Abstract Systematic literature review and network meta-analysis of first-line therapies for locally advanced/metastatic urothelial carcinoma. Drug:Enfortumab vedotin,pembrolizumab,platinum-based chemo..., Search all connections
Abstract Estimated impact of novel immune checkpoint inhibitors on reducing cancer mortality in patients with locally advanced or metastatic urothelial carcinoma in Russia. Organization:National Medical Res...,Pharmaceutical Analy...,A.S. Loginov Moscow ...,Congress:ASCO 2024, Search all connections
Abstract Tislelizumab combined with gemcitabine and cisplatin (GC) as adjuvant therapy in patients with high-risk upper urothelial carcinoma (UTUC) after surgery: A 2-year follow-up, real-world study. Drug:tislelizumab,Gemcitabine,Cisplatin,Target:Gemcitabine,PD-1,DNA,Organization:Xi’an, China,Congress:ASCO 2024, Search all connections
Abstract Single-center retrospective analysis of safety and efficacy of dose-reduced enfortumab vedotin (EV) in frail patients with metastatic urothelial carcinoma (mUC). Organization:Washington Universit...,St. Louis, MO,Congress:ASCO 2024, Search all connections
Abstract Real-world (rw) treatment (tx) patterns and clinical outcomes in patients (pts) with locally advanced/metastatic urothelial carcinoma (la/mUC): Insights from The US Oncology Network electronic health record (EHR). Organization:Rockland,Congress:ASCO 2024, Search all connections
Abstract Clinical features, genomic alterations, and survival outcomes for variant histology urothelial carcinoma. Organization:Indiana University –...,Indiana University S...,IU Simon Cancer Cent...,Congress:ASCO 2024, Search all connections
Abstract Improved overall survival with immune checkpoint inhibitors in the treatment of metastatic urothelial carcinoma: A national retrospective comparative study. Organization:Taipei Tzu Chi Hospi...,Buddhist Tzu Chi Med...,Congress:ASCO 2024, Search all connections
Abstract Avelumab (A) as neoadjuvant therapy in patients (pts) with muscle-invasive urothelial carcinoma (MIUC): Survival data of AURA trial, Oncodistinct 004. Organization:Centre Hospitalier U...,Hôpital Paris Saint-...,University Hospital ..., Search all connections
Abstract Quantitative circulating tumor DNA (ctDNA) assessment in patients (pts) with advanced urothelial carcinoma (UC) treated with pembrolizumab (pembro) or platinum-based chemotherapy (chemo) from the phase 3 KEYNOTE-361 trial. Drug:pembrolizumab,chemotherapy,Target:ctDNA,Programmed cell deat...,Organization:Yamaguchi University...,Fundación Arturo Lóp...,Fred Hutchinson Canc..., Search all connections
Abstract Dose escalation of KY-0118, PD-1, and IL-2v due-target fusion protein in patients with advanced renal clear cell carcinoma, urothelial carcinoma, and malignant melanoma. Drug:KY-0118,nivolumab,IL2wt,Target:IL-2v,PD-1,IL2-Rβγ,Organization:Novatim Immune Thera...,Shanghai, China, Gra..., Search all connections
Abstract Real-world first-line treatment patterns and outcomes in patients with locally advanced or metastatic urothelial carcinoma in the United States. Drug:Cisplatin,carboplatin,PD-1/L1 inhibitors,Target:PD-1,PD-L1,DNA,Organization:University of Kansas...,Astellas Pharma Inc., Search all connections
Abstract Informing optimal treatment (tx) sequences for platinum-eligible patients with locally advanced or metastatic urothelial carcinoma (la/mUC) in the United States: Results of a clinical simulation modeling exercise. Drug:platinum-based chemo...,avelumab,Enfortumab vedotin,Target:Avelumab,Programmed cell deat...,Nectin-4, Search all connections
Abstract A phase III randomized trial of eribulin (E) with gemcitabine (G) vs standard of care (SOC) for patients (pts) with metastatic urothelial carcinoma (mUC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937 updated design. Drug:Enfortumab vedotin,pembrolizumab,erdafitinib, Search all connections
Abstract INSIGHT-005: A new stratum of the explorative, open-labeled, phase I INSIGHT study to evaluate the feasibility and safety, as well as preliminary efficacy, of subcutaneous injections with IMP321 (eftilagimod alpha) in combination with PD-L1 inhibitor (avelumab) for metastatic or unresectable locally advanced urothelial carcinoma (UC)—IKF-s614. Drug:avelumab,Eftilagimod alpha,pembrolizumab,Target:PD-1,LAG-3,PD-L1, Search all connections
Abstract Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) for metastatic urothelial carcinoma (mUC) treatment-experienced (DAD) and with pembrolizumab (P) in treatment naïve UC (DAD-IO). Drug:SG,EV,pembrolizumab,Target:EV+P,SG,Organization:Lank Center for Geni...,Dana-Farber Cancer I...,AdventHealth Cancer ..., Search all connections
Abstract Effect of antibiotic, proton pump inhibitor, H2 blocker, metformin and statin use on outcomes with immune checkpoint inhibitors (ICIs) in patients (pts) with metastatic urothelial carcinoma (mUC) in a real-world setting. Drug:Metformin,statins,antibiotics, Search all connections
Abstract Phase 3 study of disitamab vedotin with pembrolizumab vs chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma that expresses HER2 (DV-001). Drug:Enfortumab vedotin,pembrolizumab,Disitamab vedotin,Target:Programmed cell deat...,Nectin-4, Search all connections
Abstract Updated interim analysis of a phase I/Ib study of enfortumab vedotin plus cabozantinib in patients with metastatic urothelial carcinoma. Drug:Enfortumab vedotin,pembrolizumab,cabozantinib,Target:PD-1,Nectin-4,metastatic breast ca..., Search all connections
Abstract FGFR3-mutated urothelial carcinoma of bladder and upper tract including ureter and renal pelvis: A comparative genomic profiling study. Drug:erdafitinib,taxane,vinflunine,Target:TSC1,taxane,KDM6A, Search all connections
Abstract Clinical outcomes of sacituzumab govitecan (SG) after prior exposure to enfortumab vedotin (EV) in patients with metastatic urothelial carcinoma (mUC). Drug:SG,EV,pembrolizumab,Target:PD-1,Trop-2,Organization:Memorial Sloan Kette...,Barts Cancer Institu...,Queen Mary Universit..., Search all connections
Abstract ERBB2 mutations and association with molecular phenotype in urothelial carcinoma. Organization:Dana-Farber Cancer I...,Yale University Scho...,Yale School of Medic...,Congress:ASCO 2024, Search all connections
Abstract Cost-effectiveness analysis of contemporary first-line (1L) agents in locally advanced/metastatic urothelial carcinoma (la/mUC). Drug:enfortumab vedotin-p...,gemcitabine-cisplati...,GemCis/nab-P,Target:Programmed death-lig...,DNA repair enzymes,DNA, Search all connections
Abstract Landscape analysis and oncologic outcomes in advanced urothelial carcinoma (UC) by NECTIN4 RNA expression. Drug:Enfortumab vedotin,Target:NECTIN4,Organization:University of Califo...,Northwestern Univers...,Caris Life Sciences,...,Congress:ASCO 2024, Search all connections
Abstract Evorpacept plus enfortumab vedotin in patients (Pts) with locally advanced or metastatic urothelial carcinoma (la/mUC): Phase 1a dose escalation results. Drug:Evorpacept,Enfortumab vedotin,Target:CD47 on tumor cells,Nectin-4,SIRPα,Organization:Memorial Sloan Kette...,Department of Medici...,Division of Hematolo..., Search all connections
Abstract A pilot study of tazemetostat and pembrolizumab in advanced urothelial carcinoma (ETCTN 10183). Drug:tazemetostat,pembrolizumab,Target:EZH2,PD-1,Organization:Cancer Therapy Evalu...,Clinical trial:NCI-2019-01035,Congress:ASCO 2024, Search all connections
Abstract Multi-omic analysis of the prognostic and predictive value of LAG3 expression in urothelial carcinoma. Organization:Department of Genito...,University of Virgin...,Department of Transl...,Congress:ASCO 2024, Search all connections
Abstract Response and outcomes with immune checkpoint inhibitor (ICI) in patients (pts) with urothelial carcinoma (UC) and subtype histology (SH). Organization:NYC Health + Hospita...,Attiko Hospital,Marqués de Valdecill...,Congress:ASCO 2024, Search all connections
Abstract Association of ephrinB2 (B2) expression on overall survival (OS) and resistance to PD1/L1 inhibitors (inh) in metastatic urothelial carcinoma (mUC). Drug:sEphB4-HSA,pembrolizumab,PD1/L1 inh,Target:EphB4, Search all connections
Abstract Correlation of peripheral blood monocytic myeloid-derived suppressor cells (M-MDSC) and T-cell receptor (TCR) dynamics with clinical outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) treated with nivolumab (NIVO). Drug:nivolumab,Target:PD-1,Organization:Memorial Sloan Kette...,Adaptive Phage Thera...,Genitourinary Oncolo...,Clinical trial:15-126,Congress:ASCO 2024, Search all connections
Abstract Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in patients (pts) with histological subtypes. Drug:avelumab,Target:Programmed death-lig...,Organization:INSERMU981,Billerica,Darmstadt,Clinical trial:B9991001,Congress:ASCO 2024, Search all connections
Abstract Age and other criteria influencing nontreatment of patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC): Results of a physician survey in five European countries (Eu5). Organization:Precision Value and ...,Nova Southeastern Co...,Congress:ASCO 2024, Search all connections
Abstract Enfortumab vedotin (EV) with pembrolizumab (P) versus chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Analysis of cisplatin (cis)-eligible population from EV-302/KEYNOTE-A39. Drug:EV,pembrolizumab,Gemcitabine,Target:CTLA-4,EV+P, Search all connections
Abstract Avelumab first-line maintenance (1LM) for advanced urothelial carcinoma (aUC): Long-term outcomes from JAVELIN Bladder 100 in patients (pts) with low tumor burden. Drug:avelumab,Target:Programmed death-lig...,Organization:St Bartholomew’s Hos...,Centre Jean Bernard,Yamagata University ...,Clinical trial:B9991001, Search all connections
Abstract Enfortumab vedotin (EV) with pembrolizumab (P) versus chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Analysis of the cisplatin (cis)-ineligible population from EV-302/KEYNOTE-A39. Drug:EV+P,platinum-based chemo...,Gemcitabine,Target:EV+P,ribonucleotide reduc..., Search all connections
Abstract Comparing the somatic, germline, and immune landscapes of upper tract urothelial carcinoma (UTUC) and UC of the bladder (UCB). Organization:University of Califo...,Tempus AI,University of Califo...,Congress:ASCO 2024, Search all connections
Abstract IK-175, an oral AHR inhibitor, as monotherapy and in combination with nivolumab in patients with urothelial carcinoma resistant/refractory to PD-1/L1 inhibitors. Drug:IK-175,nivolumab,Target:PD-1,AhR,Organization:Department of Urolog...,Florida Cancer Speci...,Sarah Cannon Researc...,Clinical trial:IK175-001, Search all connections
Abstract Updated results on multiple antigens stimulating cellular therapy (MASCT-I) in metastatic urothelial carcinoma: A randomized, open-label, phase I trial. Drug:MASCT-I,camrelizumab,Target:PD-1,dendritic cells,tumor-associated ant...,Organization:HRYZ Biotech Co. Ltd...,Clinical trial:HRYZ MASCT-I-1001,Congress:ASCO 2024, Search all connections
Abstract Treatment trends for metastatic urothelial carcinoma across eight Mexican centers: A global oncology perspective. Organization:Instituto Nacional d...,National Institute o...,Instituto Nacional d..., Search all connections
Abstract Characterization of complete responders to nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node–only metastatic urothelial carcinoma from the CheckMate 901 trial. Organization:Tisch Cancer Institu...,Icahn School of Medi...,Dana-Farber Cancer I..., Search all connections
Abstract Study EV-103 dose escalation/cohort A: Long-term outcome of enfortumab vedotin + pembrolizumab in first-line (1L) cisplatin-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC) with nearly 4 years of follow-up. Organization:Cleveland Clinic Ler...,University of Califo...,Yale Cancer Center, Search all connections
Abstract Erdafitinib (ERDA) vs ERDA plus cetrelimab (ERDA+CET) for patients (pts) with metastatic urothelial carcinoma (mUC) and fibroblast growth factor receptor alterations (FGFRa): Final results from the phase 2 Norse study. Organization:Barts Cancer Institu...,Department of Urolog...,Janssen Research & D..., Search all connections
Abstract Overall survival (OS) by response to first-line (1L) induction treatment with atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem in patients (pts) with metastatic urothelial carcinoma (mUC): Updated data from the IMvigor130 OS final analysis. Organization:Gregorio Marañón Uni...,IRCCS Istituto Romag...,Institute of Oncolog..., Search all connections